Schizophrenia News and Research

Latest Schizophrenia News and Research

Psychiatric inpatients have low vitamin D levels

Results from a New Zealand study show that vitamin D deficiency is common in psychiatric inpatients, particularly among patients with schizophrenia and those of Maori descent.

27 Jun 2012

CAMH releases comprehensive reviews of most effective treatments for alcohol dependence

Scientists from the Centre for Addiction and Mental Health (CAMH) have released comprehensive reviews of the most effective treatments for alcohol dependence, one of the most prevalent addictions in Canada.

27 Jun 2012

Genetic risk for schizophrenia linked to brain volume alterations

Patients with schizophrenia and their unaffected first-degree relatives show altered gray and white matter volumes in specific brain regions compared with mentally healthy individuals, researchers report.

26 Jun 2012

Liability for schizophrenia linked to cognition in mood disorders

Schizotypal traits and genetic liability for schizophrenia are associated with reduced cognitive functioning in patients with mood disorders, Japanese study results show.

26 Jun 2012

Feinstein Institute to train clinicians on how to better care for patients with schizophrenia

The Zucker Hillside Hospital campus of the Feinstein Institute for Medical Research has been approved for a $9.3+ million federal grant to train clinicians on how to better care for patients with schizophrenia.

26 Jun 2012

Superior temporal sulcus perfusion linked to QoL in schizophrenia

Schizophrenia patients with a relatively high quality of life show hypoperfusion in the superior temporal sulcus compared with those with a relatively low quality of life.

22 Jun 2012

Amygdala volume reduced in schizophrenia, not psychotic BD

Amygdala volume is reduced in patients with schizophrenia compared with those who have psychotic bipolar disorder, researchers report.

22 Jun 2012

Alexza resubmits ADASUVE NDA to U.S. FDA

Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012.

22 Jun 2012

CDSS best for assessing depression symptoms in schizophrenia

Results from a systematic review of published studies suggests that the Calgary Depression Scale for Schizophrenia is the most reliable and valid instrument for assessing depression symptoms in patients with schizophrenia.

21 Jun 2012

Study to test NAC and aspirin for people diagnosed with bipolar disorder

A commonly available pharmaceutical drug with anti-inflammatory properties and a nutritional supplement thought to have antioxidant effects are now being tested at The University of Texas Health Science Center at Houston (UTHealth) as add-on therapies for people diagnosed with bipolar disorder.

21 Jun 2012

Childhood viral CNS infections increase psychosis risk

Viral infections of the central nervous system in childhood are associated with nearly a two-fold increased risk for non-affective psychosis and schizophrenia in adulthood, a review and meta-analysis of published studies shows.

20 Jun 2012

Insight linked to gray matter volume in FEP patients

Results from an Irish study show that poor insight is associated with increased gray matter volume in subcortical and frontotemporal brain regions among patients with first-episode psychosis, but not in those with chronic schizophrenia.

20 Jun 2012

Study identifies critical neurological factor in aggression

Pathological rage can be blocked in mice, researchers have found, suggesting potential new treatments for severe aggression, a widespread trait characterized by sudden violence, explosive outbursts and hostile overreactions to stress.

20 Jun 2012

New approach to decipher roles of genes associated with autism

Fish cannot display symptoms of autism, schizophrenia or other human brain disorders. However, a team of MIT biologists has shown that zebrafish can be a useful tool for studying the genes that contribute to such disorders.

20 Jun 2012

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

Today Abbott announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease.

19 Jun 2012

Health Canada approves Sunovion’s LATUDA NDA to treat schizophrenia

Sunovion Pharmaceuticals Canada Inc. today announced that the New Drug Submission (NDS) for LATUDA (lurasidone HCl), for the treatment of adult patients with acute schizophrenia has been approved by Health Canada.

16 Jun 2012

Emotion perception impaired in patients at risk for psychosis

Patients at ultra-high risk for psychosis, as well as those with first-episode schizophrenia, show significant impairments in facial and vocal emotion recognition, researchers report.

15 Jun 2012

Oxidative stress linked to NSS severity in schizophrenia

The severity of neurologic soft signs negatively correlates with antioxidant superoxide dismutase activity in patients with schizophrenia, research shows.

14 Jun 2012

Preterm birth increases psychiatric disorder risk

Individuals born preterm are at increased risk for a range of psychiatric disorders in young adulthood, researchers report.

14 Jun 2012

IBMT linked with positive structural changes in brain connectivity

A Texas Tech University scientist studying the Chinese mindfulness meditation known as integrative body-mind training (IBMT) said he and other researchers have confirmed and expanded on changes in structural efficiency of white matter in the brain that can be related to positive behavioral changes in subjects practicing the technique for a month and a minimum of 11 hours total.

14 Jun 2012